Article | July 26, 2019

Intensified Chromatography Strategies

Source: GE Healthcare Life Sciences

By Josefin Biolik - Global Product Manager – Antibody Affinity Resins, GE Healthcare Life Sciences and Oliver Hardick - Business Leader, GE Healthcare Life Sciences


The blockbuster drug era is over, and drug manufacturers are now striving for a more diversified portfolio by targeting a greater number of monoclonal antibody (mAb) products at lower production volumes. With an increased focus on lowering drug prices, though, the key to driving down the overall costs of these therapies is making them with the same or lower capital expenditure investment. Major changes to the landscape of today’s industry are creating higher demands for flexible solutions that can minimize changeover time between campaigns. In addition, high titers from upstream and a surge in established single-use technologies (SUTs) are putting the spotlight on gaps in the process chain where other SUT options could be added to maximize productivity. With a newer toolbox of options to intensify downstream manufacturing operations, it is important to understand what factors should impact your decision.